AACR 2020:STK11和KEAP1突变影响K药一线治疗PDL1阳性患者(Keynote 042研究)

2020-04-28 网络 网络

Keynote 042是PD1单抗K药获批用于PDL1阳性(≥1%)晚期NSCLC一线治疗的基于研究。既往研究中,患者若出现STK11和KEAP1突变,则提示对免疫药物疗效差。此次分析了研究中S

Keynote 042是PD1单抗K药获批用于PDL1阳性(≥1%)晚期NSCLC一线治疗的基于研究。既往研究中,患者若出现STK11和KEAP1突变,则提示对免疫药物疗效差。此次分析了研究中STK11和KEAP1突变对K药的疗效影响。

共分析了429例患者,其中STK11和KEAP1突变率为8%和15%,3%患者出现共突变。STK11患者的PDL1表达低于无STK11突变的患者(15% vs 40%),而KEAP1阴性或阳性患者的PDL1表达相似(40% vs 40%)。STK11阳性患者比阴性的TMB表达更更高(191 vs 146),KEAP1突变患者的TMB表达也高于阴性患者(183 vs 142)。无论患者有无STK11或KEAP1突变,K药治疗的ORR、PFS和OS都相似。相比化疗,无论是STK11或KEAP1突变,K药都可以带来治疗获益。但是,从HR值来看,PFS获益在STK11及KEAP1突变患者中更低,为0.91 vs 0.75,0.96 vs 0.67。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1703440, encodeId=60d41e0344052, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10464, encryptionId=2fdf10464e6, topicName=KEYNOTE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94e330506057, createdName=tm10051991, createdTime=Mon Oct 05 08:55:57 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853117, encodeId=a26e185311e80, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1665, encryptionId=f1b41665ac, topicName=AACR 2020)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Fri Aug 07 22:55:57 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741865, encodeId=6edd1e4186517, content=<a href='/topic/show?id=672e1046575' target=_blank style='color:#2F92EE;'>#Keynote 042#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10465, encryptionId=672e1046575, topicName=Keynote 042)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202834977732, createdName=12499e01m58暂无昵称, createdTime=Sat Sep 26 04:55:57 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400462, encodeId=55c2140046254, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538764, encodeId=9d201538e64d3, content=<a href='/topic/show?id=6b2c13962d1' target=_blank style='color:#2F92EE;'>#PDL1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13962, encryptionId=6b2c13962d1, topicName=PDL1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec3513042944, createdName=qblt, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552000, encodeId=275b1552000c8, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595722, encodeId=464c1595e2277, content=<a href='/topic/show?id=b85b10452af' target=_blank style='color:#2F92EE;'>#Keap1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10452, encryptionId=b85b10452af, topicName=Keap1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3a18296289, createdName=villahu, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618731, encodeId=68631618e3131, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1703440, encodeId=60d41e0344052, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10464, encryptionId=2fdf10464e6, topicName=KEYNOTE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94e330506057, createdName=tm10051991, createdTime=Mon Oct 05 08:55:57 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853117, encodeId=a26e185311e80, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1665, encryptionId=f1b41665ac, topicName=AACR 2020)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Fri Aug 07 22:55:57 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741865, encodeId=6edd1e4186517, content=<a href='/topic/show?id=672e1046575' target=_blank style='color:#2F92EE;'>#Keynote 042#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10465, encryptionId=672e1046575, topicName=Keynote 042)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202834977732, createdName=12499e01m58暂无昵称, createdTime=Sat Sep 26 04:55:57 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400462, encodeId=55c2140046254, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538764, encodeId=9d201538e64d3, content=<a href='/topic/show?id=6b2c13962d1' target=_blank style='color:#2F92EE;'>#PDL1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13962, encryptionId=6b2c13962d1, topicName=PDL1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec3513042944, createdName=qblt, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552000, encodeId=275b1552000c8, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595722, encodeId=464c1595e2277, content=<a href='/topic/show?id=b85b10452af' target=_blank style='color:#2F92EE;'>#Keap1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10452, encryptionId=b85b10452af, topicName=Keap1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3a18296289, createdName=villahu, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618731, encodeId=68631618e3131, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=)]
    2020-08-07 tamgche
  3. [GetPortalCommentsPageByObjectIdResponse(id=1703440, encodeId=60d41e0344052, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10464, encryptionId=2fdf10464e6, topicName=KEYNOTE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94e330506057, createdName=tm10051991, createdTime=Mon Oct 05 08:55:57 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853117, encodeId=a26e185311e80, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1665, encryptionId=f1b41665ac, topicName=AACR 2020)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Fri Aug 07 22:55:57 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741865, encodeId=6edd1e4186517, content=<a href='/topic/show?id=672e1046575' target=_blank style='color:#2F92EE;'>#Keynote 042#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10465, encryptionId=672e1046575, topicName=Keynote 042)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202834977732, createdName=12499e01m58暂无昵称, createdTime=Sat Sep 26 04:55:57 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400462, encodeId=55c2140046254, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538764, encodeId=9d201538e64d3, content=<a href='/topic/show?id=6b2c13962d1' target=_blank style='color:#2F92EE;'>#PDL1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13962, encryptionId=6b2c13962d1, topicName=PDL1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec3513042944, createdName=qblt, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552000, encodeId=275b1552000c8, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595722, encodeId=464c1595e2277, content=<a href='/topic/show?id=b85b10452af' target=_blank style='color:#2F92EE;'>#Keap1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10452, encryptionId=b85b10452af, topicName=Keap1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3a18296289, createdName=villahu, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618731, encodeId=68631618e3131, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1703440, encodeId=60d41e0344052, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10464, encryptionId=2fdf10464e6, topicName=KEYNOTE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94e330506057, createdName=tm10051991, createdTime=Mon Oct 05 08:55:57 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853117, encodeId=a26e185311e80, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1665, encryptionId=f1b41665ac, topicName=AACR 2020)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Fri Aug 07 22:55:57 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741865, encodeId=6edd1e4186517, content=<a href='/topic/show?id=672e1046575' target=_blank style='color:#2F92EE;'>#Keynote 042#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10465, encryptionId=672e1046575, topicName=Keynote 042)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202834977732, createdName=12499e01m58暂无昵称, createdTime=Sat Sep 26 04:55:57 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400462, encodeId=55c2140046254, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538764, encodeId=9d201538e64d3, content=<a href='/topic/show?id=6b2c13962d1' target=_blank style='color:#2F92EE;'>#PDL1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13962, encryptionId=6b2c13962d1, topicName=PDL1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec3513042944, createdName=qblt, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552000, encodeId=275b1552000c8, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595722, encodeId=464c1595e2277, content=<a href='/topic/show?id=b85b10452af' target=_blank style='color:#2F92EE;'>#Keap1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10452, encryptionId=b85b10452af, topicName=Keap1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3a18296289, createdName=villahu, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618731, encodeId=68631618e3131, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=)]
    2020-04-30 10518094zz
  5. [GetPortalCommentsPageByObjectIdResponse(id=1703440, encodeId=60d41e0344052, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10464, encryptionId=2fdf10464e6, topicName=KEYNOTE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94e330506057, createdName=tm10051991, createdTime=Mon Oct 05 08:55:57 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853117, encodeId=a26e185311e80, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1665, encryptionId=f1b41665ac, topicName=AACR 2020)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Fri Aug 07 22:55:57 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741865, encodeId=6edd1e4186517, content=<a href='/topic/show?id=672e1046575' target=_blank style='color:#2F92EE;'>#Keynote 042#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10465, encryptionId=672e1046575, topicName=Keynote 042)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202834977732, createdName=12499e01m58暂无昵称, createdTime=Sat Sep 26 04:55:57 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400462, encodeId=55c2140046254, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538764, encodeId=9d201538e64d3, content=<a href='/topic/show?id=6b2c13962d1' target=_blank style='color:#2F92EE;'>#PDL1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13962, encryptionId=6b2c13962d1, topicName=PDL1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec3513042944, createdName=qblt, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552000, encodeId=275b1552000c8, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595722, encodeId=464c1595e2277, content=<a href='/topic/show?id=b85b10452af' target=_blank style='color:#2F92EE;'>#Keap1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10452, encryptionId=b85b10452af, topicName=Keap1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3a18296289, createdName=villahu, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618731, encodeId=68631618e3131, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=)]
    2020-04-30 qblt
  6. [GetPortalCommentsPageByObjectIdResponse(id=1703440, encodeId=60d41e0344052, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10464, encryptionId=2fdf10464e6, topicName=KEYNOTE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94e330506057, createdName=tm10051991, createdTime=Mon Oct 05 08:55:57 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853117, encodeId=a26e185311e80, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1665, encryptionId=f1b41665ac, topicName=AACR 2020)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Fri Aug 07 22:55:57 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741865, encodeId=6edd1e4186517, content=<a href='/topic/show?id=672e1046575' target=_blank style='color:#2F92EE;'>#Keynote 042#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10465, encryptionId=672e1046575, topicName=Keynote 042)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202834977732, createdName=12499e01m58暂无昵称, createdTime=Sat Sep 26 04:55:57 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400462, encodeId=55c2140046254, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538764, encodeId=9d201538e64d3, content=<a href='/topic/show?id=6b2c13962d1' target=_blank style='color:#2F92EE;'>#PDL1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13962, encryptionId=6b2c13962d1, topicName=PDL1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec3513042944, createdName=qblt, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552000, encodeId=275b1552000c8, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595722, encodeId=464c1595e2277, content=<a href='/topic/show?id=b85b10452af' target=_blank style='color:#2F92EE;'>#Keap1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10452, encryptionId=b85b10452af, topicName=Keap1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3a18296289, createdName=villahu, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618731, encodeId=68631618e3131, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=)]
    2020-04-30 Luyuxie_14
  7. [GetPortalCommentsPageByObjectIdResponse(id=1703440, encodeId=60d41e0344052, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10464, encryptionId=2fdf10464e6, topicName=KEYNOTE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94e330506057, createdName=tm10051991, createdTime=Mon Oct 05 08:55:57 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853117, encodeId=a26e185311e80, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1665, encryptionId=f1b41665ac, topicName=AACR 2020)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Fri Aug 07 22:55:57 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741865, encodeId=6edd1e4186517, content=<a href='/topic/show?id=672e1046575' target=_blank style='color:#2F92EE;'>#Keynote 042#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10465, encryptionId=672e1046575, topicName=Keynote 042)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202834977732, createdName=12499e01m58暂无昵称, createdTime=Sat Sep 26 04:55:57 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400462, encodeId=55c2140046254, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538764, encodeId=9d201538e64d3, content=<a href='/topic/show?id=6b2c13962d1' target=_blank style='color:#2F92EE;'>#PDL1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13962, encryptionId=6b2c13962d1, topicName=PDL1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec3513042944, createdName=qblt, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552000, encodeId=275b1552000c8, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595722, encodeId=464c1595e2277, content=<a href='/topic/show?id=b85b10452af' target=_blank style='color:#2F92EE;'>#Keap1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10452, encryptionId=b85b10452af, topicName=Keap1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3a18296289, createdName=villahu, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618731, encodeId=68631618e3131, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=)]
    2020-04-30 villahu
  8. [GetPortalCommentsPageByObjectIdResponse(id=1703440, encodeId=60d41e0344052, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10464, encryptionId=2fdf10464e6, topicName=KEYNOTE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94e330506057, createdName=tm10051991, createdTime=Mon Oct 05 08:55:57 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853117, encodeId=a26e185311e80, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1665, encryptionId=f1b41665ac, topicName=AACR 2020)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Fri Aug 07 22:55:57 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741865, encodeId=6edd1e4186517, content=<a href='/topic/show?id=672e1046575' target=_blank style='color:#2F92EE;'>#Keynote 042#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10465, encryptionId=672e1046575, topicName=Keynote 042)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202834977732, createdName=12499e01m58暂无昵称, createdTime=Sat Sep 26 04:55:57 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400462, encodeId=55c2140046254, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538764, encodeId=9d201538e64d3, content=<a href='/topic/show?id=6b2c13962d1' target=_blank style='color:#2F92EE;'>#PDL1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13962, encryptionId=6b2c13962d1, topicName=PDL1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec3513042944, createdName=qblt, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552000, encodeId=275b1552000c8, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595722, encodeId=464c1595e2277, content=<a href='/topic/show?id=b85b10452af' target=_blank style='color:#2F92EE;'>#Keap1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10452, encryptionId=b85b10452af, topicName=Keap1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3a18296289, createdName=villahu, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618731, encodeId=68631618e3131, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Thu Apr 30 05:55:57 CST 2020, time=2020-04-30, status=1, ipAttribution=)]

相关资讯

PLoS Genet:激活这个蛋白,便有望抵御阿兹海默病

日前,英国伦敦大学学院 (University College London) 的研究人员发现,一种称为 Keap1 的蛋白可能预防阿兹海默病 (Alzheimer’s Disease, AD) 和其它神经退行性疾病的新靶点。Keap1 的作用是抑制具有保护神经元功能的 Nrf2 蛋白。通过抑制 Keap1 的功能,研究人员能够激活 Nrf2 蛋白功能,保护神经细胞在病理环境下不受损伤。

CLIN CANCER RES:KEAP1和NFE2L2突变非小细胞肺癌临床病理特征

KEAP1和NFE2L2突变与非小细胞肺癌中鳞状细胞癌形成有关。但是对于其发病率,病理特征,分子和临床表现以及系统治疗反应尚不清楚。CLIN CANCER RES近期发表了一篇文章,研究这一问题。